7.23.1 ProSavin Clinical Trials Performance to Date
7.23.2 Will ProSavin Lead The Charge In PD Gene Therapy?
7.24 CERE-120 (Ceregene): Delivering Neurotrophic Factors
7.24.1 Repairing Dopaminergic Neurons in Human Beings
7.24.2 Can New Trial Succeed Where Past Attempts Failed?
7.25 AAV-hAADC-2 (Genzyme): AAV Gene Therapy Due to Complete Phase 1 in Q1 2013
7.26 Collategene (Vical/AnGes): Angiogenic Gene Therapy
7.27 AAV2-GDNF (uniQure)
7.28 Cellular Therapies
7.29 Spheramine (Bayer): RPE Cells to Make Levodopa
7.30 NTCELL (Living Cell Technologies)
7.31 Stem Cell Approaches to PD
7.32 NeuroGeneration - PD Treatment with Autologous Neural Stem Cells
7.33 BrainStorm Cell Therapeutics - Proprietary NurOwn Cells
7.34 Therapeutic Vaccine Approaches
7.35 Affitope PD01 (Affiris) - The First Vaccine for PD
8. Qualitative Industry Analysis: Drivers and Restraints
8.1 Strengths: Parkinson's Disease is a Prevalent and Treatable Disease8.2 Weaknesses: Products on the Market Have Limitations and Can Be Superseded8.3 Opportunities: Neurodegenerative Disorder Treatments Are a Fertile R&D Area8.4 Threats: New Parkinson's Treatments May Be Subject to Political, Commercial and Social Pressures
9.1 Interview with Dr Kieran Breen , Parkinson's UK
9.1.1 Repositioning Drugs, and Bigger Databases: Developments in the PD Market in 2011-2012
9.1.2 The New Non-Dopaminergic Drugs
9.1.3 The Challenge of Disease Modification
9.1.4 New Formulations of Levodopa
9.1.5 The Next Decade for Parkinson's Disease
9.2 Interview with Chris Maggos , Addex Therapeutics
9.2.1 What Differentiates Addex's Candidates?
9.2.2 Understanding the Glutamatergic Approach
9.2.3 Dipraglurant's Progr
Copyright©2012 PR Newswire.
All rights reserved